Literature DB >> 1310951

B-cell lymphoproliferative disorders in solid-organ transplant patients: detection of Epstein-Barr virus by in situ hybridization.

L C Berg1, C M Copenhaver, V A Morrison, S A Gruber, D L Dunn, K Gajl-Peczalska, J G Strickler.   

Abstract

B-cell lymphoproliferative disorders (BLPDs) occur in approximately 2% of transplant recipients and are frequently fatal. Indirect serologic evidence has implicated Epstein-Barr virus (EBV) as an etiologic factor in these lesions. Direct evidence of the presence of EBV in these lesions has been obtained in relatively few cases. We used in situ hybridization (ISH) with a probe for the BamHI-W region of the EBV genome to study 52 tissue specimens from 28 solid-organ transplant patients who had BLPD. Epstein-Barr virus-infected lymphoid cells were identified in 26 of these 28 patients. The two patients without ISH evidence of EBV infection showed no distinctive clinical, morphologic, or serologic features. Previous filter-hybridization studies of these two patients had demonstrated evidence of EBV infection. Seven additional transplant patients without evidence of BLPD were studied as controls and showed no evidence of EBV in their lymphoid cells by ISH. These data provide further support for the etiologic role of EBV in the pathogenesis of posttransplantation lymphoproliferative disorders.

Entities:  

Mesh:

Year:  1992        PMID: 1310951     DOI: 10.1016/0046-8177(92)90237-w

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Epstein-Barr virus in malignancies in renal transplant recipients in Japan.

Authors:  Y Hoshida; Y Tomita; M Ohsawa; X Ning; K Aozasa
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.

Authors:  W Chen; N R Cooper
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

3.  A possible role for Epstein-Barr virus in tumorigenesis after immunosuppression in cases of renal transplantation.

Authors:  T Suzuki; Y Takano; K Yamashita; K Sato; A Kakita; M Okudaira
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  A rat monoclonal anti-(human CD2) and L-leucine methyl ester impacts on human/SCID mouse graft and B lymphoproliferative syndrome.

Authors:  F Bombil; J P Kints; X Havaux; J M Scheiff; H Bazin; D Latinne
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

5.  Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin.

Authors:  A Chadburn; N Suciu-Foca; E Cesarman; E Reed; R E Michler; D M Knowles
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

Review 6.  The antiviral prophylaxis of post-transplant lymphoproliferative disorder.

Authors:  C L Davis
Journal:  Springer Semin Immunopathol       Date:  1998

7.  The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in Korea: incidence of disease entities by age groups.

Authors:  Eun-Yoon Cho; Ki-Hyun Kim; Won-Seog Kim; Keon Hee Yoo; Hong-Hoe Koo; Young-Hyeh Ko
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.